Pharmacogenetic Testing in an Outpatient Population of Patients With Depression

Completed · Not applicable

Conditions studied: Depression

In brief

This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).

Key facts

Study ID

NCT02497027

Run by

Avera McKennan Hospital & University Health Center

People needed

83

Starts

2015-02-01

Expected to finish

2017-04-01

Last updated by the study team

2017-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current primary or secondary diagnosis of Major Depressive Disorder or Depressive Disorder Not Otherwise Specified
• Have moderate to severe depression as identified by PHQ-9 scoring of 10 or greater
• Taking or be newly prescribed an anti-depressant or anti-psychotic medication
• Able to provide informed consent
• Prescribing physician practices at the Avera Medical Group University Psychiatry Associates clinic in Sioux Falls, SD

You may not qualify if…

• Pregnant or breastfeeding
• Active and/or unstable diagnosis of substance abuse, excluding nicotine
• Primary diagnosis of dementia, bipolar disorder (any type), schizophrenia, schizoaffective disorder, or personality disorder

Where it is running

• Avera McKennan Hospital & University Health Center — Sioux Falls, South Dakota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.